Description: VBI Vaccines Inc., a biotechnology company, engages in the formulation, development, and delivery of vaccines. It develops Thermostable IM flu vaccine for the needs of pediatric, adult, and geriatric markets; Thermostable IM measles vaccines; Thermostable Oral flu and Shigella vaccines; prophylactic VLP-based vaccines to prevent cytomegalovirus infections and diseases; and seasonal/pandemic influenza vaccines. The company serves customers in the United States and internationally. VBI Vaccines Inc. was formerly known as Variation Biotechnologies (US), Inc. The company was founded in 2001 and is based in Cambridge, Massachusetts with research facilities in Ottawa, Canada.
Home Page: www.vbivaccines.com
VBIV Technical Analysis
160 Second Street
Cambridge,
MA
02142
United States
Phone:
617 830 3031
Officers
| Name | Title |
|---|---|
| Mr. Jeffery R. Baxter F.C.M.A., FCMA | Pres, CEO & Director |
| Mr. Christopher McNulty | CFO, Head of Bus. Devel. & Director |
| Dr. David Evander Anderson | Chief Scientific Officer |
| Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. | Chief Medical Officer |
| Nicole Anderson | Director of Corp. Communications & Investor Relations |
| Ms. Athena Kartsaklis | Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer |
| Ms. Nell Beattie | Chief Bus. Officer |
| Mr. Avi Mazaltov | Global Head of Manufacturing & GM of SciVac |
| Mr. Misha Nossov | Sr. VP of Global Commercial Supply Strategy & Head of Europe |
| Mr. T. Adam Buckley | Sr. VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5634 |
| Price-to-Sales TTM: | 139.5181 |
| IPO Date: | 1995-08-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 149 |